Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Posterior Default Network Modulation in Alcohol Use Disorder

18. listopadu 2026 aktualizováno: Martin Plawecki, Indiana University

This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.

rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.

Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.

Typ studie

Intervenční

Zápis (Odhadovaný)

70

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Ann E Kosobud, PhD
  • Telefonní číslo: 3172740087
  • E-mail: akosobud@iu.edu

Studijní záloha kontaktů

  • Jméno: James M Hays
  • Telefonní číslo: 3179486550
  • E-mail: haysjm@iu.edu

Studijní místa

    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46201
        • IU Health University Hospital
        • Vrchní vyšetřovatel:
          • Martin H Plawecki, MD, PhD
        • Kontakt:
          • Study Recruiter
          • Telefonní číslo: 3179486551
          • E-mail: erptest@iu.edu

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

21 let až 55 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Men and women aged 21 - 55
  • Alcohol Use Disorder diagnostic criteria based on Interview, Screening, and Measures of at least moderate severity
  • ≥7 or 14 drinks/week average over the last month or ≥ 3 or 4 drinks/occasion for women and men respectively
  • Positive alcohol cue reactivity screening
  • Systematic Delay Discounting behavior
  • Right-handed

Exclusion Criteria:

  • Physical Exam, Vital Signs, Electrocardiogram, Laboratory Values, or screening assessment precluding safe participation or experimental procedures
  • Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 177 ≥8 or reported significant risk symptoms
  • MRI contraindications
  • Pregnant or breast-feeding women; Women who do not attest to using accepted forms of birth control
  • Current or desire for AUD or substance use treatment
  • Medical conditions (e.g., seizure disorder) that may influence participant safety or study outcome)
  • Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine and evidence of intoxication
  • Medications or dosage changes (past 30 days) that could influence participant safety or data (e.g., antidepressants, antipsychotics, benzodiazepines, etc.) or interact with alcohol
  • Current/history of neurological disease of cerebral origin, head injury with > 20 min loss of consciousness, medical treatment impacting MRI data, or serious psychiatric illness (bipolar disorder, psychosis).
  • Positive BrAC reading precluding visit completion
  • Actively suicidal or are at serious suicidal risk
  • Left-handed or ambidextrous
  • First degree family member with seizure disorder
  • Inability to understand English study instructions
  • Intoxication from any substance terminates an experimental day and will be considered for overall exclusion or study participation.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Sequence 1

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Experimentální: Sequence 2

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast [Flavor > Water] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart
Change in cue-induced craving after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in impulsivity assessed using a delay discounting task after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in pDMN BOLD responses during a delay discounting task after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in pDMN functional connectivity during alcohol tasting after TBS treatment.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and salience network after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in within-DMN functional connectivity during a delay discounting task after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and cognitive control areas after TBS.
Časové okno: 3 single day laboratory sessions scheduled 7-14 days apart

Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting.

3 single day laboratory sessions scheduled 7-14 days apart

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Martin H Plawecki, MD, PhD, Department of Psychiatry, Indiana University School of Medicine
  • Vrchní vyšetřovatel: David Kareken, PhD, Department of Neurology, Indiana University School of Medicine

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

1. června 2031

Dokončení studie (Odhadovaný)

1. června 2031

Termíny zápisu do studia

První předloženo

12. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

18. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 24457
  • R01AA031671 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.

Časový rámec sdílení IPD

After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

Kritéria přístupu pro sdílení IPD

On request to the PIs

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • ICF

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .